Discussions marquées : New vaccine introduction

JUST RELEASED: Rotavirus Surveillance, Safety and Economic Data before Vaccine Introduction: a Global Perspective from the World Health Organization Global Rotavirus Surveillance Network

A new issue of Vaccine is now available: Rotavirus Surveillance, Safety and Economic Data before Vaccine Introduction: a Global Perspective from the World Health Organization Global Rotavirus Surveillance Network 
Edited by Adam L. Cohen, Negar Aliabadi, Fatima Serhan, Jacqueline E. Tate, Patrick Zuber, Umesh D. Parashar This can be accessed from: https://www.sciencedirect.com/journal/vaccine/vol/36/issue/51?dgcid=raven_sd_via_email

New HPV communication materials

Catharina de Kat Publié dans :
WHO/Europe is working with immunization programmes across the European Region to help them raise awareness about HPV vaccination, address obstacles to high uptake and prepare for HPV vaccine introduction where it is not yet part of the routine immunization programme. As part of this work WHO/Europe has led or collaborated in the production of information materials, including the following resources: Video: HPV and cervical cancer – a personal story Video: How the HPV vaccine works Video: Monitoring the side effects of the HPV vaccine Q&A about the HPV virus and vaccine Talking with patients and parents about HPV vaccination for girls: Information for health care professionals A field guide to qualitative research for new vaccine introduction
To access these and more WHO resources related to HPV go to: http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-immunization/vaccine-preventable-diseases/human-papillomavirus-hpv2

Anyone from Brazil and Mali?

Is there anyone here who works in immunization program in Brazil and Mali? I need to ask some questions regarding immunization schedule and their respective immunization program. I tried reviewing available literature and publications online but there are some data that seem inconsistent.  Please send me a private message here, or email me through raguindin.md@gmail.com. Thank you!

Towards evidence-based decision making for strengthening immunization supply chains: a review of literature

Immunization programs in low-income countries are facing the most ambitious targets of the last four decades: reach every child with existing and many new vaccines. The original immunization supply chains (iSCs) design, put in place in the 1970’s, is struggling to exceed an 80% coverage rate and is unable to support the increasing volume, complexity, bulk, and cost of vaccines. In recent years, the iSC community has recognized the need to encourage more comprehensive iSC redesigns to address the changing requirements of immunization programs. These “next-generation” immunization supply chains represent a fundamental shift in how iSCs are designed and managed in low- and middle-income countries. Next-generation supply chains are not defined by a specific design, but instead share a set of characteristics that represent a fundamental change in how EPI supply chains have historically operated. The purpose of a next-generation iSC is to improve product availability and ensure all children are reached with a full set of immunizations in a cost-effective manner. They are designed to embrace the five fundamentals of system design, data, people, cold chain equipment and continuous improvement to deliver immunization services reliably, efficiently and safely. For those leading the change-management process in countries, evidence related to next-generation iSC is limited and not easily accessible. VillageReach compiled a list of critical questions regarding the impact of shifting to next-generation iSC from stakeholders at the country and global levels and used these questions to develop a research and evidence framework. Three broad themes were identified and these cover the “what”, “why” and “how” of next-generation iSCs. VillageReach conducted a review guided by these key themes and found little evidence in the peer-reviewed literature linking holistic supply chain design or even individual supply chain improvements to improved outcomes. While the grey literature includes more evidence from LMICs, it is primarily related to the effect of supply chain improvements on commodity availability. However, a challenge is there is no single repository for these works, hence it is not easily accessible to advocates or key stakeholders.

Several themes arose from the literature review. First, documentation of the problem is strong. We found substantial evidence in the literature documenting the challenges experienced or anticipated with new vaccine introductions on the supply chain including; increase in cost, waste, reduced availability and the creation of bottlenecks. There is similar documentation around challenges with keeping the cold chain maintained at the right temperature, and the impact of vial size on storage and transport. Second, modeling is an important source of data. Modeling studies in peer-reviewed literature demonstrate the anticipated outcomes of supply chain improvements including improvements in availability and efficiency. Third, costing of existing systems is useful, but limited costing of improved systems exists. The EPI Costing (EPIC) studies are a rich source of information that identify cost drivers of EPI programs, including supply chain components; provide new insights into total cost and efficiency metrics; and help answer questions related to the cost of existing systems. Additional work is expected through the Immunization Delivery Cost (IDC) evidence project. Limited work has been done however, to evaluate the cost difference between current iSC and next-generation iSC systems. Fourth, grey literature does include evidence, particularly on availability of commodities. Case studies, supply chain partner reports, impact briefs, and blogs provide evidence of supply chain improvements for vaccines and other commodities. In particular, repositories are available from USAID|DELIVER and Project Optimize. The grey literature also provides more examples of holistic next-generation iSC impact. Some of the powerful examples we have found were from Nigeria, Senegal, Zambia, Mozambique and Benin (see detailed report attached). While there is much discussion regarding the importance of evidence-based decision making, our work to date has highlighted that the existing literature does not answer many of the priority questions decision-makers are currently asking regarding the move to next-generation immunization supply chains. Moreover, some of the existing evidence is not easily accessed or interpreted by decision-makers. Finally, significant gaps exist regarding the process for move to a next-generation iSC and the resources required. Join the discussion:
If you are interested in discussing how we can gather, develop and share evidence regarding iSC improvement, please contact:melissa.west@villagereach.orgorbvudzai.magadzire@villagereach.org

Supplement The Future of Immunization in Africa - is still open for submission

Raoul Kamadjeu Publié dans :
The upcoming supplement "The Future of Immunization in Africa Supplement", guest-editored by Bob Davis (Am Red Cross) , Helen Rees (Wits U) and Steve Cochi (GID, CDC), is still open for submission. The supplement will be published in mid 2017 in the Pan African Medical Journal. Submit your manuscript now for consideration. Follow the link below for more about the supplement http://www.panafrican-med-journal.com/mailalert/MA02122016.htm

Ebola vaccine trial in Sierra Leone battles against fear and logistics

From today's Guardian Health workers face suspicion and a lack of cold storage as they test the Ebola vaccine http://www.theguardian.com/global-development/2016/mar/10/ebola-vaccine-trial-sierra-leone-fear-logistics-immunisations Dr Tamba Manye, who works for the World Health Organisation (WHO) in Tonkolili, says logistics need to be improved before the unlicensed vaccine can be made more widely available.“There is no cold chain facility in Sierra Leone that can deal with the vaccine because it has to be stored at minus 80 degrees celcius. The only facility is in Guinea, so we had to fly the vaccines from there.

IVAC VIMS Report on Global Vaccine Introduction - September 2015 Now Available!

Thuy-Linh Nguyen Publié dans :
The September 2015 Vaccine Information Management System (VIMS)Report on Global Vaccine Introductionfrom IVAC at Johns Hopkins is now availablehere. Recent vaccine introduction updates (since May 2015) include: · Pneumococcal conjugate vaccine (PCV) has been introduced in Eritrea, Guinea-Bissau, Lebanon, Lesotho, and Portugal. · Rotavirus vaccine has been introduced in Kiribati. · Inactivated polio vaccine (IPV) has been introduced in Benin, Bhutan, Cameroon, Central African Republic, Chad, Cote D'Ivoire, Guyana, Kiribati, TFYR Macedonia, Morocco, Niger, Pakistan, Papua New Guinea, Saint Vincent and the Grenadines, Sri Lanka, and Sudan.
Current and archived reports, as well as the PowerPoint slide deck with the latest report graphics, can also be found on the VIMS page of the IVAC website at:http://www.jhsph.edu/ivac/vims/ What is the VIMS Report? The VIMS report displays data and figures on the introduction status of Hib, pneumococcal, rotavirus, and inactivated polio vaccines both globally and in the 73 Gavi countries. The images and text in the report describe: · How many countries have introduced each vaccine or plan to in the future · National levels of vaccine coverage and access, globally and in Gavi countries · Vaccine introduction trends over time · Vaccine introduction status of each of the 194 countries, listed individually

NEW IPV ADVOCACY TOOLS!

Thirty countries have now introduced IPV vaccine as part of objective 2 of the Polio Eradication and Endgame Strategic Plan. In August, the second of the polio endemic countries, Pakistan, introduced IPV nationally. There are now 30 countries that have introduced the vaccine. Nigeria, the other endemic country to introduce IPV has now also successfully gone one year without a case of reported wild poliovirus. To document the experience of early adopters of IPV, Johns Hopkins Bloomberg School of Public Health’s International Vaccine Access Center (IVAC) worked with four countries, WHO, UNICEF, Gavi, the Task Force for Global Health and the Bill and Melinda Gates Foundation to create a series of written cases studies, a multi-country video, individual country videos and guidance for countries to develop their own case studies and human interest stories to support the monumental effort to introduce IPV into 126 countries previously using only OPV and help strengthen their routine immunization programs. These materials, now available on the IVAC and WHO websites as well as YouTube include: • Short graphic movie about global IPV introduction; • Film Series on IPV introduction: Albania, Nepal, Nigeria, and Tunisia; • Case Studies of IPV introduction in Albania, Nigeria, and Tunisia; • Guidelines for documenting vaccine introductions and human interest stories We hope you will join us in marking this occasion. Please feel free to use these materials to support your efforts. Please contact Katie Gorham at: Kgorham3@jhu.edu if you need additional assistance.

Cost projections of Decade of Vaccine

Dear All, Please find attached the article recently published on cost projections of DoV. The costing analysis examines the vaccine costs, supply chain costs, and service delivery costs of immunization programs for routine immunization and for supplemental immunization activities (SIAs) for vaccines related to 18 antigens in 94 countries across the decade, 2011–2020. The analysis shows that the delivery of the full vaccination program across 94 countries would cost a total of $62 billion (95% uncertainty range: $43–$87 billion) over the decade, including $51 billion($34–$73 billion) for routine immunization and $11 billion ($7–$17 billion) for SIAs. More than half of these costs stem from service delivery at $34 billion ($21–$51 billion)—with an additional $24 billion($13–$41 billion) in vaccine costs and $4 billion ($3–$5 billion) in supply chain costs. The study, financed by BMGF, has been conducted by Johns Hopkins and University of Pittsburgh. Best regards, Claudio

IVAC VIMS Report on Global Vaccine Introduction - January 2015 (Now with IPV)

Thuy-Linh Nguyen Publié dans :
The January 2015 edition of the IVAC VIMS Report on Global Vaccine Introduction is now available at http://www.jhsph.edu/research/centers-and-institutes/ivac/vims/IVAC-VIMS-Report-2015-Jan.pdf

New in the January edition is the addition of an inactivated polio vaccine (IPV) section in the report.

IVAC VIMS Report on Global Vaccine Introduction - September 2014

Thuy-Linh Nguyen Publié dans :
The IVAC VIMS Report on Global Vaccine Introduction - September 2014 is out!

Recent updates (since March 2014) include:

-South Sudan's introduction of Haemophilus influenzae type b (Hib) vaccine in July 2014 marks a significant milestone in global health, as Hib-containing pentavalent vaccine is now available in all 73 Gavi countries. To read IVAC's reflections on this historic moment, click here.
-Pneumococcal conjugate vaccine (PCV) has been introduced in Niger, Republic of Korea, Swaziland, and Togo.
-Rotavirus vaccine has been introduced in Angola, Cameroon, Congo, Djibouti, Eritrea, Estonia, Kenya, Madagascar, New Zealand, Niger, Sierra Leone, Togo, Uzbekistan, and Zimbabwe.



The VIMS report displays data and figures on the introduction status of Hib, pneumococcal, and rotavirus vaccines both globally and in the 73 Gavi-eligible countries. The images and text in the report describe:

-How many countries have introduced each vaccine or plan to in the future
-National levels of vaccine coverage and access, globally and in Gavi countries
-Vaccine introduction trends over time
-Vaccine introduction status of each of the 194 countries, listed individually


This report is produced on a quarterly basis. Current and past reports can be accessed at http://www.jhsph.edu/research/centers-and-institutes/ivac/vims/

IVAC VIMS Report on Global Vaccine Introduction - December 2013

Thuy-Linh Nguyen Publié dans :
IVAC-VIMS-Dec-2013-Report.pdf

This report provides data and figures on the introduction status of Haemophilus influenzae type b (Hib), pneumococcal, and rotavirus vaccines both globally and in 73 GAVI-eligible countries using information stored in the Vaccine Information Management System (VIMS) online database, managed by the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health. The images and text describe how many countries have introduced each vaccine or plan to in the future, global and GAVI rates of coverage and access, historical trends of the rate of introduction globally, and the vaccine introduction status of every country individually.

This report is produced on a quarterly basis. Current and past reports can be accessed at www.jhsph.edu/research/centers-and-institutes/ivac/vims/

For any questions regarding VIMS or the VIMS reports, please contact [email=vims@jhsph.edu]vims@jhsph.edu[/email].

Operational guidelines for introducing newer vaccine: pentavalent

I have attached a PPT on operational guidelines to introduce the newer pentavalent vaccine for further editing/inputs from the viewers. This will give an opportunity to refresh and re-orient the service providers on DPT and hepatitis B also. Operational-guidelines-New-Pentavalent-Vaccine.pdf

Post 00677e : Paho Publication

Moderator Publié dans :
POST 00677E : PAHO PUBLICATION 23 May 2004
________________________________

Mylena Pinzon (mailtoinzonmi@paho.org) from the Pan American Health
Organization (PAHO) informs us that the book "Vaccines: Preventing Disease
& Protecting Health "has just been published. It is available only in
English for the moment but a Spanish version is expected by the end of
August and a French one later. For more details, see her message here below
and the document attached.
________________________________

The Pan American Health Organization (PAHO), Regional Office of the World
Health Organization (WHO) for the Americas, recently published the book
"Vaccines: Preventing Disease & Protecting Health".

This books chapters discuss progress made through vaccines used in most of
the world's immunization programs, describe the status of introduction of
the newest vaccines currently available to immunization programs, review
progress in the development of vaccines against some bacterial and viral
diseases, as well as the quest for vaccines against HIV/AIDS, malaria, and
dengue. A section addresses technological aspects of vaccine development,
such as new concepts, including DNA vaccine technology, and new adjuvants
and delivery systems. Diseases that may be used for bioterrorism, such as
smallpox and anthrax, also are discussed. The roster of authors reads like
a "Who's Who "in public health and in vaccine development and use: Dr.
Anthony Fauci, Dr. Donald Henderson, Peter Hotez, Dr. Ciro de Quadros,
among other important authors.

We are sure that participants of your list will be very interested to find
out about this book.

Regards,

Mylena .

PAHO Publications Program
Washington DC USA

--------------------------------------------------------------------------------------

Visit the TECHNET21 Website at http://www.technet21.org

You will find instructions to subscribe, a direct access to archives, links to reference documents and other features.
______________________________________________________________________________

To UNSUBSCRIBE, send a message to : mailto:LISTSERV@listes.ulaval.ca
Leave the subject area BLANK
In the message body, write unsubscribe TECHNET21E
______________________________________________________________________________

The World Health Organization and UNICEF support TechNet21. The TechNet21 e-Forum is a communication/information tool for generation of ideas on how to improve immunization services. It is moderated by Claude Letarte and is hosted in cooperation with the Centre de internationale en san, Canada (http://www.ccisd.org)
______________________________________________________________________________
##text##
  • Page :
  • 1